Managing Prostate Cancer During [177Lu]Lu-PSMA-617 Radioligand Therapy: Tips for Oncology Nurses.

BACKGROUND

Radioligand therapy (RLT), particularly lutetium 177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 is an approved targeted treatment for metastatic castration-resistant prostate cancer.

OBJECTIVES

This article aims to equip oncology nurses with essential knowledge about and strategies for managing patients with prostate cancer undergoing [177Lu]Lu-PSMA-617 RLT.

METHODS

RLT is associated with low-grade and self-limited toxicities, such as fatigue, xerostomia, and nausea. Reviewing the literature and real-world clinical experience, nurses can learn to support patients in the outpatient setting.

FINDINGS: Nurses should focus on patient selection, management of preexisting conditions, and supportive care strategies to mitigate common side effects. Nurses should monitor blood counts, prostate-specific antigen levels, and renal function throughout treatment cycles. Patient education about post-therapy radiation safety and waste disposal ensures safe home environments.